STOK
Stoke Therapeutics, Inc. (STOK) ESG Analysis Analysis (2026)
Environmental
R&D intensity at 6.1% of revenue suggests a meaningful product-development footprint, but peers with heavier industrial or manufacturing exposure typically face larger direct emissions burdens.
Debt-to-equity of 0.01 implies limited balance-sheet pressure to fund decarbonization, yet this metric is less differentiating than peers with explicit climate disclosures and targets.
Net debt to EBITDA of 0.52 indicates modest leverage, which can support environmental compliance spending, although it does not itself demonstrate stronger environmental management than peers.
No filing-based emissions, energy, or waste metrics were provided, so relative environmental positioning remains only moderately evidenced versus peers with disclosed sustainability KPIs.
Social
Stock-based compensation at 1.1% of revenue suggests a relatively restrained dilution burden, which can support employee alignment, but it is not a direct social-performance indicator versus peers.
High gross margin of 84.7% may reflect a more asset-light operating model, which often reduces frontline labor intensity compared with labor-heavy peers, but disclosure is insufficient to confirm workforce practices.
R&D intensity indicates continued investment in specialized talent, which can strengthen human-capital retention relative to peers, though no turnover, safety, or diversity data were provided.
Absent filing evidence on labor relations, DEI, or product responsibility, the social profile appears neutral-to-moderately favorable rather than clearly leading peers.
Governance
Very low debt-to-equity suggests conservative capital structure discipline, which reduces creditor pressure and often aligns with stronger governance than more levered peers.
Stock-based compensation at 1.1% of revenue appears contained, limiting dilution risk and suggesting comparatively disciplined executive incentive design versus peers with heavier equity issuance.
R&D spending of 6.1% of revenue indicates management is allocating capital toward long-term innovation, which can support governance quality when paired with restrained leverage.
No filing-based evidence of board independence, audit issues, or controversies was provided, so governance is assessed as stronger than average but not top-tier versus peers.
Overall Score
STOK appears modestly above average on governance and neutral-to-moderate on environmental and social factors, but limited disclosure prevents a stronger peer-relative ESG assessment.
Score Driver: Conservative Leverage And Restrained Stock-Based Compensation Versus Peers.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Stoke Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

